Reilly Herbert Faulkner Iii buys $4,533,093 stake in Amgen (AMGN)

Amgen (AMGN) : Reilly Herbert Faulkner Iii scooped up 580 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 11, 2016. The investment management firm now holds a total of 26,933 shares of Amgen which is valued at $4,533,093.Amgen makes up approximately 3.41% of Reilly Herbert Faulkner Iii’s portfolio.

Other Hedge Funds, Including , Jacobs Coca boosted its stake in AMGN in the latest quarter, The investment management firm added 803 additional shares and now holds a total of 38,586 shares of Amgen which is valued at $6,494,410. Amgen makes up approx 1.46% of Jacobs Coca’s portfolio.Independent Portfolio Consultants reduced its stake in AMGN by selling 483 shares or 3.37% in the most recent quarter. The Hedge Fund company now holds 13,845 shares of AMGN which is valued at $2,315,438. Amgen makes up approx 0.73% of Independent Portfolio Consultants’s portfolio. Curbstone Financial Management Corp added AMGN to its portfolio by purchasing 2,410 company shares during the most recent quarter which is valued at $403,048. Amgen makes up approx 0.13% of Curbstone Financial Management Corp’s portfolio.Private Asset Management Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 1,630 shares of Amgen which is valued at $272,601. Amgen makes up approx 0.05% of Private Asset Management Inc’s portfolio. Lvm Capital Management Ltdmi sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 69,845 shares of AMGN which is valued $11,680,878.

Amgen closed down -3.99 points or -2.37% at $164.32 with 27,61,896 shares getting traded on Tuesday. Post opening the session at $167.82, the shares hit an intraday low of $163.51 and an intraday high of $167.82 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.